• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [223 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Direct acting antivirals for chronic hepatitis C genotype 1 in select populations: emerging evidence of clinical effectiveness and safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Re-treatment with direct acting antivirals for chronic hepatitis C genotype 1: emerging evidence of clinical effectiveness and safety
2014 Blue Cross Blue Shield Association (BCBS) Cost-effectiveness studies of new hepatitis C treatments
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Triple therapy for hepatitis C in previous non-responders: a review of the clinical effectiveness and safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Ombitasvir/paritaprevir/ritonavir and dasabuvir
2014 Haute Autorite de sante (HAS) [Assessment of non-invasive methods for measuring liver fibrosis in chronic hepatitis B. Initial assessment and follow-up of non-treated adult patients]
2014 Malaysian Health Technology Assessment (MaHTAS) Rapid blood test device for HIV, HBV, HCV, & syphillis
2014 Andalusian Health Technology Assessment Area (AETSA) [Summary of evidence for efficacy and safety of sofosbuvir in transplant patients with chronic hepatitis c]
2014 Andalusian Health Technology Assessment Area (AETSA) [Summary of evidence for efficacy and safety of sofosbuvir in patients with chronic hepatitis c waiting for liver transplant]
2014 Andalusian Health Technology Assessment Area (AETSA) [Summary of evidence for efficacy and safety of sofosbuvir in patients with chronic hepatitis c coinfected with human immunodeficiency virus]
2014 Andalusian Health Technology Assessment Area (AETSA) [Selection criteria for direct antiviral agents for patients with chronic hepatitis c in a severe clinical situation in the SSPA]
2014 Andalusian Health Technology Assessment Area (AETSA) [Updating of selection criteria for direct antiviral agents for patients with chronic hepatitis c in a severe clinical situation in the SSPA]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-05 (sofosbuvir)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pilot study: conjoint analysis in the indication "hepatitis C"]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Simeprevir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-18 (simeprevir)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daclatasvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2013 NIHR Horizon Scanning Centre (NIHR HSC) ABT-450/ritonavir/ABT-267 in combination with ABT-333 for chronic genotype-1 hepatitis C infection
2013 NIHR Horizon Scanning Centre (NIHR HSC) Sofosbuvir with ledipasvir for hepatitis C, genotype 1
2013 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tenofovir disoproxil fumarate (Viread®)
2013 NIHR Horizon Scanning Centre (NIHR HSC) Daclatasvir and asunaprevir for hepatitis C infection
2013 Canadian Agency for Drugs and Technologies in Health (CADTH) Protease inhibitor use for chronic hepatitis C infection in prior null responders and recurrent hepatitis C infection post liver transplant: a review of the clinical evidence
2013 National Institute for Health and Care Excellence (NICE) Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people. NICE technology appraisal guidance 300
2012 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Entecavir (Baraclude®)
2012 Canadian Agency for Drugs and Technologies in Health (CADTH) Retreatment, switching and extended therapy with boceprevir and telaprevir for chronic hepatitis C infection: a review of the clinical effectiveness and safety
2012 Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of anemia and neutropenia in patients with chronic hepatitis C infection treated with peginterferon-ribavirin based regimens with or without protease inhibitors: a review of the clinical evidence
2012 Canadian Agency for Drugs and Technologies in Health (CADTH) Protease inhibitor use for chronic hepatitis C infection in special populations: a review of the clinical evidence and guidelines
2012 Canadian Agency for Drugs and Technologies in Health (CADTH) Immune response to hepatitis B vaccination: a review of the clinical evidence
2012 NIHR Horizon Scanning Centre (NIHR HSC) Simeprevir for chronic hepatitis C infection
2012 NIHR Horizon Scanning Centre (NIHR HSC) Simeprevir for hepatitis C – first line
2012 Andalusian Health Technology Assessment Area (AETSA) [Protease inhibitors (Boceprevir and telaprevir) in the treatment of chronic HCV infection: relative efficacy, safety and efficiency]
2012 Agency for Healthcare Research and Quality (AHRQ) Interventions to improve patient adherence to hepatitis C treatment: comparative effectiveness
2012 Agency for Healthcare Research and Quality (AHRQ) Treatment for hepatitis C virus infection in adults
2012 Agency for Healthcare Research and Quality (AHRQ) Screening for hepatitis C virus infection in adults
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Telaprevir - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2011 NIHR Health Technology Assessment programme Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation
2011 Belgian Health Care Knowledge Centre (KCE) Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium - Part 2
2011 NIHR Health Technology Assessment programme Boceprevir for the treatment of genotype 1 chronic hepatitis C
2011 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tenofovir disoproxil fumarate (Viread®)
2011 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Boceprevir - Benefit assessment according to 35a Social Code Book V (dossier assessment)]
2010 Belgian Health Care Knowledge Centre (KCE) Cost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium. Part 1: Literature review and results of a national study
2010 HAYES, Inc. FIBROSpect II test (Prometheus Laboratories Inc.) for diagnosis of liver fibrosis in patients with hepatitis c
2010 NIHR Horizon Scanning Centre (NIHR HSC) Telaprevir (VX-950) for hepatitis C
2010 Committee for New Health Technology Assessment (CNHTA) [HBV drug resistance mutation[multiplex-PCR]]
2010 NIHR Horizon Scanning Centre (NIHR HSC) Boceprevir for hepatitis C
2010 NIHR Health Technology Assessment programme Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection
2010 National Institute for Health and Care Excellence (NICE) Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. NICE technology appraisal guidance 200
2009 NIHR Health Technology Assessment programme Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation
2009 Health Council of the Netherlands Gezondheidsraad (GR) General vaccination against hepatitis B revisited
2009 NIHR Health Technology Assessment programme Telbivudine for the treatment of chronic hepatitis B infection
2009 NIHR Health Technology Assessment programme Entecavir for the treatment of chronic hepatitis B infection
2009 National Institute for Health and Care Excellence (NICE) Tenofovir disoproxil for the treatment of chronic hepatitis B. NICE technology appraisal guidance 173
2008 Agency for Healthcare Research and Quality (AHRQ) Management of chronic hepatitis B
2008 Belgian Health Care Knowledge Centre (KCE) Evaluation of universal and targeted hepatitis A vaccination programs in Belgium
2008 Canadian Agency for Drugs and Technologies in Health (CADTH) Granulocyte-colony stimulating factor for antiviral-associated neutropenia: Systematic review and economic evaluation
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tenofovir disoproxil fumarate (Viread®) for the treatment of hepatitis B
2008 National Institute for Health and Care Excellence (NICE) Entecavir for the treatment of chronic hepatitis B. NICE technology appraisal guidance 153
2008 National Institute for Health and Care Excellence (NICE) Telbivudine for the treatment of chronic hepatitis B. NICE technology appraisal guidance 154
2007 Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical and cost-effectiveness of interferon-based therapies for chronic hepatitis C virus infection
2007 Canadian Agency for Drugs and Technologies in Health (CADTH) Pegylated interferon combined with ribavirin for chronic hepatitis C virus infection: an economic evaluation
2007 Haute Autorite de sante (HAS) Detection of hepatitis C virus (HCV) RNA in sperm fractions
2007 Haute Autorite de sante (HAS) Assessment of non-invasive techniques to measure liver fibrosis in chronic viral hepatitis C and B
2007 NIHR Horizon Scanning Centre (NIHR HSC) Tenofovir disoproxil fumarate for hepatitis B: horizon scanning technology briefing
2007 NIHR Health Technology Assessment programme Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation
2007 NIHR Health Technology Assessment programme A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment
2007 Adelaide Health Technology Assessment (AHTA) Perinatal Hepatitis C screening
2007 HAYES, Inc. Hepatitis A vaccine
2007 Medical Services Advisory Committee (MSAC) Hepatitis B DNA testing
2006 Quality Improvement Scotland (NHS QIS ) Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
2006 Institute of Technology Assessment (ITA) Chronic hepatitis C: decision analytic modeling
2006 NIHR Horizon Scanning Centre (NIHR HSC) Taribavirin hydrochloride for chronic hepatitis C virus: horizon scanning review
2006 NIHR Horizon Scanning Centre (NIHR HSC) Telbivudine for chronic hepatitis B: horizon scanning review
2006 NIHR Health Technology Assessment programme Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation
2006 NIHR Health Technology Assessment programme Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation
2006 NIHR Health Technology Assessment programme The cost-effectiveness of testing for hepatitis C in former injecting drug users
2006 Quality Improvement Scotland (NHS QIS ) Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
2006 National Institute for Health and Care Excellence (NICE) Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B. NICE technology appraisal guidance 96
2005 Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Treatment strategy for chronic Hepatitis C - systematic review
2005 NIHR Horizon Scanning Centre (NIHR HSC) Thymalfasin (Zadaxin) for hepatitis C virus - horizon scanning review
2005 NIHR Horizon Scanning Centre (NIHR HSC) FibroTest-ActiTest for diagnosis and monitoring of fibrosis in chronic liver conditions - horizon scanning review
2005 Institute for Clinical Systems Improvement (ICSI) Antiviral treatment for chronic hepatitis C
2005 Adelaide Health Technology Assessment (AHTA) FibroTest-ActiTest (update): a diagnostic test for liver fibrosis in patients with hepatitis C
2004 Agency for Healthcare Research and Quality (AHRQ) Screening for hepatitis C virus infection
2004 NIHR Horizon Scanning Centre (NIHR HSC) FibroTest-ActiTest, a diagnostic test for liver fibrosis in patients with hepatitis C - horizon scanning review
2004 Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Inteferon-based therapies for chronic Hepatitis C virus infection: an assessment of clinical outcomes
2004 HAYES, Inc. Interferon/ribavirin therapy for hepatitis C
2004 NIHR Health Technology Assessment programme Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation
2004 Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Serum markers of fibrosis and inflammation in chronichepatitis C - update of previous report
2004 Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Quantification of hepatic fibrosis by transient elastography (Fibroscan (R)) - preliminary report
2004 Institute for Clinical Effectiveness and Health Policy (IECS) Treatment with pegylated interferon in hepatitis C
2004 Institute of Technology Assessment (ITA) Chronic hepatitis C: implications for therapy and economic resources in Austria
2004 Quality Improvement Scotland (NHS QIS ) Interferon alfa (pegylated and non-pegylated) and ribavarin for the treatment of chronic hepatitis C
2004 Adelaide Health Technology Assessment (AHTA) FibroTest-ActiTest: A diagnostic test for liver fibrosis in patients with hepatitis C
2003 Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Adefovir dipivoxil for hepatitis B virus infection
2003 Health Council of the Netherlands Gezondheidsraad (GR) Vaccination of children against hepatitis B
2003 Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) Introduction of hepatitis B vaccine in the childrens immunization programme in Denmark: A health technology assessment
2003 Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Serum markers of fibrosis and inflammation in chronichepatitis C - systematic review, expert panel
2003 German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) Antiviral therapy for patients with chronic hepatitis C in Germany - evaluation of effectiveness and cost-effectiveness of initial combination therapy with interferon / peginterferon plus ribavirin
2003 Institute for Clinical Effectiveness and Health Policy (IECS) Treatment with interferon in hepatitis C